




RealRate

PHARMACEUTICAL 2017

DMK Pharmaceuticals Corp
Rank 148 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of DMK Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DMK Pharmaceuticals Corp compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 128% points. The greatest weakness of DMK Pharmaceuticals Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 17% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	7,070
Cost of Goods Sold	0
Intangible Assets	25,777
Liabilities, Current	8,611
Liabilities, Non-Current	0
Other Assets	42
Other Compr. Net Income	0
Other Expenses	279
Other Liabilities	3,896
Other Net Income	1,192
Other Revenues	6,474
Property and Equipment	4,897
Research and Development	9,697
Selling, General and Administrative Expense	17,128

Output Variable	Value in 1000 USD
Assets	37,786
Liabilities	12,507
Expenses	27,104
Revenues	6,474
Stockholders Equity	25,280
Net Income	-19,437
Comprehensive Net Income	-19,437
BaseVar	42,531
ECR before Limited Liability	142%
Economic Capital Ratio	262%